ASTRAZENECA PLC (NY: AZN)
66.86 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 22, 2014  /  Add to My Watchlist      
(AZN) Community Analysis from
April 23, 2014
(Jutia Group, 2/6/14)
[Reuters] - AstraZeneca is moving an experimental Alzheimer's drug into late-stage development, taking on U.S. rival Merck & Co which announced plans...(read more)
(Jutia Group, 1/9/14)
[at Seeking Alpha] - Both AstraZeneca PLC ( AZN ) and the Bristol-Myers Squibb Co. ( BMY ) are anticipated...(read more)
(Stock Blog Hub, 9/9/13)
AstraZeneca (AZN) recently presented data on naloxegol (25 mg once daily) from two pivotal phase III studies (KODIAC-04 and -05) at the Digestive Disease Week (DDW) meeting. Top-line results...(read more)
AstraZeneca (AZN) Company Overview

AstraZeneca is one of the world's largest pharmaceutical companies, with FY2009 sales of $32.8 billion and $7.5 billion in profits.[1] AstraZeneca's wide-ranging portfolio of products includes some of the world's most successful drugs. Among other blockbusters, AstraZeneca produces cholesterol fighter Crestor and the ubiquitous "purple pill" Nexium, one of the best-selling drugs in history.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here